Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

BACKGROUND: Pazopanib is a standard treatment for metastatic renal cell carcinoma (mRCC), and 800 mg/daily is considered the optimal dose. However, some patients require dose modification because of toxicity. Whether a reduced dose of pazopanib is as effective as the standard dose in achieving clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Grassi, Paolo, Verzoni, Elena, Ratta, Raffaele, Porcu, Luca, Prisciandaro, Michele, Mennitto, Alessia, Calareso, Giuseppina, de Braud, Filippo, Procopio, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629143/
https://www.ncbi.nlm.nih.gov/pubmed/28801802
http://dx.doi.org/10.1007/s40268-017-0203-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629143/
https://www.ncbi.nlm.nih.gov/pubmed/28801802
http://dx.doi.org/10.1007/s40268-017-0203-y

Ejemplares similares